OLX10212

OLX10212 is an investigational **cell-penetrating asymmetric small interfering RNA (cp-asiRNA)** therapeutic developed for the treatment of **age-related macular degeneration (AMD)**, including both geographic atrophy (GA, dry AMD) and neovascular (wet) AMD. Its mechanism is based on silencing **inflammation pathways** implicated in AMD pathogenesis via RNA interference (RNAi), employing a proprietary asymmetric siRNA platform technology. OLX10212 is administered by **intravitreal injection** and is designed to offer greater specificity and extended durability compared to conventional siRNA, targeting disease pathways upstream of VEGF. Phase 1 clinical trials have demonstrated favorable safety, tolerability, and preliminary efficacy, with no significant systemic or ocular adverse effects apart from mild injection-related events. The drug is being advanced by OliX Pharmaceuticals, a pioneer in RNAi therapeutics, and represents a novel approach aiming to address both the dry and wet forms of AMD, potentially reducing treatment burden for patients[1][2][3][4][5][6][7].

Other names

OLX10212OLX-10212OLX 10212